Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | APG-115 |
Synonyms | |
Therapy Description |
APG-115, a derivative of SAR405838, inhibits MDM2 and its interaction with p53, thereby stabilizing and activating wild-type p53, which may result in antitumor activity and also synergizes with PD-1 inhibitors (PMID: 28498808, PMID: 31779710). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APG-115 | APG115|APG 115|Alrizomadlin | MDM2 Inhibitor 21 | APG-115, a derivative of SAR405838, inhibits MDM2 and its interaction with p53, thereby stabilizing and activating wild-type p53, which may result in antitumor activity and also synergizes with PD-1 inhibitors (PMID: 28498808, PMID: 31779710). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | thyroid gland papillary carcinoma | sensitive | APG-115 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808). | 28498808 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03781986 | Phase Ib/II | APG-115 | APG-115 in Salivary Gland Cancer Trial | Recruiting | USA | 0 |
NCT04496349 | Phase II | APG-115 + APG-2575 APG-115 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL | Recruiting | USA | 0 |
NCT02935907 | Phase I | APG-115 | APG-115 in Patients With Advanced Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT04358393 | Phase Ib/II | APG-115 + Azacitidine APG-115 | A Study of APG-115 Alone or in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |